Coronary/Structural Heart

VenusP-Valve(TM) obtains CE marking under MDR and debuts in Europe as China’s first valve product

HANGZHOU, China, April 11, 2022 /PRNewswire/ — On April 8th, 2022, VenusP-ValveTM, Venus Medtech’s in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, received CE marking under the Medical Devices Regulation (MDR) to be marketed in Europe. Designed to treat patients with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract […]

scPharmaceuticals Inc. Announces Resubmission of FUROSCIX® New Drug Application

Anticipates Q4 2022 commercial launch, if approved BURLINGTON, Mass., April 11, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the […]

Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program

The company plans to develop Lilly’s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for treatment of atherosclerotic cardiovascular disease and potentially other conditions OXFORD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program […]

CeloNova Announces New Strategic Direction Focused on Creating Partnership

Opportunities Featuring Proprietary Surface Coated Technologies CARLSBAD, Calif., April 7, 2022 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, today announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking […]

Triastek Receives FDA IND Clearance for 3D Printed Product of Blockbuster Molecule

NANJING, China, April 7, 2022 /PRNewswire/ — Triastek, Inc. (“Triastek”) recently announced that the United States Food and Drug Administration (FDA) has granted permission to begin clinical studies of its Investigational New Drug (IND) 505(b)(2) application for a 3D printed drug product – T20.  It is Triastek’s second product receiving IND clearance from the […]

CathWorks and Quest International Announce Global Post-Sales Technical Service Support Partnership

KFAR-SABA, Israel and IRVINE, Calif., April 6, 2022 /PRNewswire/ — CathWorks, an original equipment manufacturer (OEM), and Quest International, a global service support provider to the OEMs, announced today they have signed a post-sales technical service support agreement that Quest International becomes the preferred technical service delivery partner for end-to-end service support of CathWorks’ fast-growing […]

New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure

Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart that was presented on April 2nd at the American College of Cardiology (ACC) 71st Scientific Sessions […]

United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation

In subjects with PAH, transition from Tyvaso® to Tyvaso DPI™ demonstrated safety and tolerability with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported outcomes Tyvaso DPI safety confirmed through 51 weeks of optional extension phase data with no study drug-related serious adverse events FDA action on […]

Valo Health Acquires TARA Biosystems Creating First of its Kind Vertically Integrated Cardiovascular Platform

Combined Company to Spearhead Transformation of Cardiovascular Disease Drug Discovery and Development BOSTON, April 5, 2022 /PRNewswire/ — Valo Health, LLC (“Valo”), announced today the acquisition of TARA Biosystems, Inc. (“TARA”), a New York City-based cardiovascular disease biotechnology company, creating the first of its kind vertically integrated cardiovascular drug discovery and development platform. The combination of TARA’s proprietary […]